These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 8564851)

  • 1. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome.
    Teller JK; Russo C; DeBusk LM; Angelini G; Zaccheo D; Dagna-Bricarelli F; Scartezzini P; Bertolini S; Mann DM; Tabaton M; Gambetti P
    Nat Med; 1996 Jan; 2(1):93-5. PubMed ID: 8564851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reverse relationship between beta-amyloid precursor protein and beta-amyloid peptide plaques in Down's syndrome versus sporadic/familial Alzheimer's disease.
    Egensperger R; Weggen S; Ida N; Multhaup G; Schnabel R; Beyreuther K; Bayer TA
    Acta Neuropathol; 1999 Feb; 97(2):113-8. PubMed ID: 9928821
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
    Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
    Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease.
    Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM
    Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early accumulation of heparan sulfate in neurons and in the beta-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome.
    Snow AD; Mar H; Nochlin D; Sekiguchi RT; Kimata K; Koike Y; Wight TN
    Am J Pathol; 1990 Nov; 137(5):1253-70. PubMed ID: 2146882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in beta-amyloid (beta/A4) deposition in human patients with Down's syndrome and sporadic Alzheimer's disease.
    Armstrong RA
    Neurosci Lett; 1994 Mar; 169(1-2):133-6. PubMed ID: 8047269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome.
    Busciglio J; Pelsman A; Wong C; Pigino G; Yuan M; Mori H; Yankner BA
    Neuron; 2002 Feb; 33(5):677-88. PubMed ID: 11879646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heterogeneity of water-soluble amyloid beta-peptide in Alzheimer's disease and Down's syndrome brains.
    Russo C; Saido TC; DeBusk LM; Tabaton M; Gambetti P; Teller JK
    FEBS Lett; 1997 Jun; 409(3):411-6. PubMed ID: 9224700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The developmental and aging changes of Down's syndrome cell adhesion molecule expression in normal and Down's syndrome brains.
    Saito Y; Oka A; Mizuguchi M; Motonaga K; Mori Y; Becker LE; Arima K; Miyauchi J; Takashima S
    Acta Neuropathol; 2000 Dec; 100(6):654-64. PubMed ID: 11078217
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abundance of the longer A beta 42 in neocortical and cerebrovascular amyloid beta deposits in Swedish familial Alzheimer's disease and Down's syndrome.
    Kalaria RN; Cohen DL; Greenberg BD; Savage MJ; Bogdanovic NE; Winblad B; Lannfelt L; Adem A
    Neuroreport; 1996 May; 7(8):1377-81. PubMed ID: 8856679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protein expression of BACE1, BACE2 and APP in Down syndrome brains.
    Cheon MS; Dierssen M; Kim SH; Lubec G
    Amino Acids; 2008 Aug; 35(2):339-43. PubMed ID: 18163181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of amyloid (A4) protein deposits within the cerebral and cerebellar cortex in Down's syndrome and Alzheimer's disease.
    Mann DM; Jones D; Prinja D; Purkiss MS
    Acta Neuropathol; 1990; 80(3):318-27. PubMed ID: 1698007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-Amyloid peptide and amyloid precursor proteins in olfactory mucosa of patients with Alzheimer's disease, Parkinson's disease, and Down syndrome.
    Crino PB; Martin JA; Hill WD; Greenberg B; Lee VM; Trojanowski JQ
    Ann Otol Rhinol Laryngol; 1995 Aug; 104(8):655-61. PubMed ID: 7639477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
    Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE
    PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.
    Rumble B; Retallack R; Hilbich C; Simms G; Multhaup G; Martins R; Hockey A; Montgomery P; Beyreuther K; Masters CL
    N Engl J Med; 1989 Jun; 320(22):1446-52. PubMed ID: 2566117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The up-regulation of metabotropic glutamate receptor 5 (mGluR5) in Down's syndrome brains.
    Oka A; Takashima S
    Acta Neuropathol; 1999 Mar; 97(3):275-8. PubMed ID: 10090675
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Life-long overexpression of S100beta in Down's syndrome: implications for Alzheimer pathogenesis.
    Griffin WS; Sheng JG; McKenzie JE; Royston MC; Gentleman SM; Brumback RA; Cork LC; Del Bigio MR; Roberts GW; Mrak RE
    Neurobiol Aging; 1998; 19(5):401-5. PubMed ID: 9880042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Characterization of amyloid beta protein species in the plasma, cerebrospinal fluid and brains of patients with Alzheimer's disease].
    Tamaoka A
    Nihon Ronen Igakkai Zasshi; 1998 Apr; 35(4):273-7. PubMed ID: 9643008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain.
    Russo C; Salis S; Dolcini V; Venezia V; Song XH; Teller JK; Schettini G
    Neurobiol Dis; 2001 Feb; 8(1):173-80. PubMed ID: 11162251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.